KRAS exon 2/3 mutations occur in ~6% of CLL and are associated with trisomy 12 CLL, promoting an increase in RAS/ERK downstream signaling and constitutive activation of the MAPK signaling pathway[44]. The gene discussed is KRAS; the disease is B-cell chronic lymphocytic leukemia.